-
Something wrong with this record ?
Safety and diagnostic efficacy of gadoteridol for magnetic resonance imaging of the brain and spine in children 2 years of age and younger
CC. Shah, MV. Spampinato, HA. Parmar, OA. Raslan, P. Tomà, DDM. Lin, J. Vymazal, C. Colosimo, DS. Enterline
Language English Country Germany
Document type Journal Article
NLK
ProQuest Central
from 1997-01-01 to 1 year ago
CINAHL Plus with Full Text (EBSCOhost)
from 2008-01-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2000-01-01 to 1 year ago
Nursing & Allied Health Database (ProQuest)
from 1997-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 1997-01-01 to 1 year ago
Family Health Database (ProQuest)
from 1997-01-01 to 1 year ago
- MeSH
- Gadolinium adverse effects MeSH
- Heterocyclic Compounds * adverse effects MeSH
- Infant MeSH
- Contrast Media adverse effects MeSH
- Humans MeSH
- Magnetic Resonance Imaging MeSH
- Brain MeSH
- Brain Neoplasms * MeSH
- Infant, Newborn MeSH
- Organometallic Compounds * adverse effects MeSH
- Child, Preschool MeSH
- Retrospective Studies MeSH
- Check Tag
- Infant MeSH
- Humans MeSH
- Infant, Newborn MeSH
- Child, Preschool MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: Neonates and young children require efficacious magnetic resonance imaging (MRI) examinations but are potentially more susceptible to the short- and long-term adverse effects of gadolinium-based contrast agents due to the immaturity of their body functions. OBJECTIVE: To evaluate the acute safety and diagnostic efficacy of gadoteridol (ProHance) for contrast-enhanced MRI of the central nervous system (CNS) in children ≤2 years of age. MATERIALS AND METHODS: One hundred twenty-five children ≤2 years old (including 57 children <6 months old) who underwent contrast-enhanced MRI of the CNS with gadoteridol at 0.1 mmol/kg body weight were retrospectively enrolled at five imaging centers. Safety data were assessed for acute/subacute adverse events in the 48 h following gadoteridol administration and, when available, vital signs, electrocardiogram (ECG) and clinical laboratory values obtained from blood samples taken from 48 h before until 48 h following the MRI exam. The efficacy of gadoteridol-enhanced MRI compared to unenhanced MRI for disease diagnosis was evaluated prospectively by three blinded, unaffiliated readers. RESULTS: Thirteen changes of laboratory values (11 mild, 1 moderate, 1 unspecified) were reported as adverse events in 7 (5.6%) patients. A relationship to gadoteridol was deemed possible though doubtful for two of these adverse events in two patients (1.6%). There were no clinical adverse events, no serious adverse events and no clinically meaningful changes in vital signs or ECG recordings. Accurate differentiation of tumor from non-neoplastic disease, and exact matching of specific MRI-determined diagnoses with on-site final diagnoses, was achieved in significantly more patients by each reader following the evaluation of combined pre- and post-contrast images compared to pre-contrast images alone (84.6-88.0% vs. 70.9-76.9%; P≤0.006 and 67.5-79.5% vs. 47.0-66.7%; P≤0.011, respectively). CONCLUSION: Gadoteridol at 0.1 mmol/kg body weight is safe, well tolerated and effective for contrast-enhanced MRI of the CNS in children ≤2 years of age.
Bambino Gesù Children's Hospital Rome Italy
C S Mott Children's Hospital University of Michigan Ann Arbor MI USA
Davis Medical Center University of California Sacramento CA USA
Department of Radiology Na Homolce Hospital Prague Czech Republic
Duke University School of Medicine Durham NC USA
Johns Hopkins University School of Medicine Baltimore MD USA
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22003857
- 003
- CZ-PrNML
- 005
- 20220127145804.0
- 007
- ta
- 008
- 220113s2021 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00247-021-05069-w $2 doi
- 035 __
- $a (PubMed)33950270
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Shah, Chetan C $u Pediatric Radiology, Wolfson Children's Hospital, Nemours Children's Health System, 800 Prudential Drive, Jacksonville, FL, 32207, USA. Chetan.Shah@nemours.org
- 245 10
- $a Safety and diagnostic efficacy of gadoteridol for magnetic resonance imaging of the brain and spine in children 2 years of age and younger / $c CC. Shah, MV. Spampinato, HA. Parmar, OA. Raslan, P. Tomà, DDM. Lin, J. Vymazal, C. Colosimo, DS. Enterline
- 520 9_
- $a BACKGROUND: Neonates and young children require efficacious magnetic resonance imaging (MRI) examinations but are potentially more susceptible to the short- and long-term adverse effects of gadolinium-based contrast agents due to the immaturity of their body functions. OBJECTIVE: To evaluate the acute safety and diagnostic efficacy of gadoteridol (ProHance) for contrast-enhanced MRI of the central nervous system (CNS) in children ≤2 years of age. MATERIALS AND METHODS: One hundred twenty-five children ≤2 years old (including 57 children <6 months old) who underwent contrast-enhanced MRI of the CNS with gadoteridol at 0.1 mmol/kg body weight were retrospectively enrolled at five imaging centers. Safety data were assessed for acute/subacute adverse events in the 48 h following gadoteridol administration and, when available, vital signs, electrocardiogram (ECG) and clinical laboratory values obtained from blood samples taken from 48 h before until 48 h following the MRI exam. The efficacy of gadoteridol-enhanced MRI compared to unenhanced MRI for disease diagnosis was evaluated prospectively by three blinded, unaffiliated readers. RESULTS: Thirteen changes of laboratory values (11 mild, 1 moderate, 1 unspecified) were reported as adverse events in 7 (5.6%) patients. A relationship to gadoteridol was deemed possible though doubtful for two of these adverse events in two patients (1.6%). There were no clinical adverse events, no serious adverse events and no clinically meaningful changes in vital signs or ECG recordings. Accurate differentiation of tumor from non-neoplastic disease, and exact matching of specific MRI-determined diagnoses with on-site final diagnoses, was achieved in significantly more patients by each reader following the evaluation of combined pre- and post-contrast images compared to pre-contrast images alone (84.6-88.0% vs. 70.9-76.9%; P≤0.006 and 67.5-79.5% vs. 47.0-66.7%; P≤0.011, respectively). CONCLUSION: Gadoteridol at 0.1 mmol/kg body weight is safe, well tolerated and effective for contrast-enhanced MRI of the CNS in children ≤2 years of age.
- 650 _2
- $a mozek $7 D001921
- 650 12
- $a nádory mozku $7 D001932
- 650 _2
- $a předškolní dítě $7 D002675
- 650 _2
- $a kontrastní látky $x škodlivé účinky $7 D003287
- 650 _2
- $a gadolinium $x škodlivé účinky $7 D005682
- 650 12
- $a heterocyklické sloučeniny $x škodlivé účinky $7 D006571
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a novorozenec $7 D007231
- 650 _2
- $a magnetická rezonanční tomografie $7 D008279
- 650 12
- $a organokovové sloučeniny $x škodlivé účinky $7 D009942
- 650 _2
- $a retrospektivní studie $7 D012189
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Spampinato, Maria Vittoria $u Medical University of South Carolina, Charleston, SC, USA
- 700 1_
- $a Parmar, Hemant A $u C.S. Mott Children's Hospital, University of Michigan, Ann Arbor, MI, USA
- 700 1_
- $a Raslan, Osama A $u Davis Medical Center, University of California, Sacramento, CA, USA
- 700 1_
- $a Tomà, Paolo $u Bambino Gesù Children's Hospital, Rome, Italy
- 700 1_
- $a Lin, Doris D M $u Johns Hopkins University School of Medicine, Baltimore, MD, USA
- 700 1_
- $a Vymazal, Josef $u Department of Radiology, Na Homolce Hospital, Prague, Czech Republic
- 700 1_
- $a Colosimo, Cesare $u Insitute of Radiology, Radiodiagnostica e Neuroradiologia, Fondazione Policlinico Universitario "A. Gemelli," Universita Cattolica del Sacro Cuore, Rome, Italy
- 700 1_
- $a Enterline, David S $u Duke University School of Medicine, Durham, NC, USA
- 773 0_
- $w MED00003740 $t Pediatric radiology $x 1432-1998 $g Roč. 51, č. 10 (2021), s. 1895-1906
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33950270 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220113 $b ABA008
- 991 __
- $a 20220127145800 $b ABA008
- 999 __
- $a ok $b bmc $g 1751352 $s 1155006
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 51 $c 10 $d 1895-1906 $e 20210505 $i 1432-1998 $m Pediatric radiology $n Pediatr Radiol $x MED00003740
- LZP __
- $a Pubmed-20220113